The global Urinary Tract Cancer Market is expected to foresee significant growth. APAC to lead the growth!

Theurinary tract cancer market is expected to witness a CAGR of around 18% during the forecast period. Urinary tract cancer is a type of cancer that affects the urethra, bladder, and renal pelvic. The tube that carries urine from the bladder to the outside of the body is affected by urethral cancer. Immunotherapy and chemotherapy are the two major procedures for the treatment of urinary tract cancer. The growth of the global market for urinary tract cancer is driven by the increasing number of cases of bladder cancer, the rise in the elderly population, and the number of bladder cancer research centers. However, the risk associated with the use of drugs employed in urinary tract cancer restrains the market growth. On the other hand, new opportunities will arise in the coming years as global healthcare expenditure rise. For instance, the World Cancer Research Fund International estimates that there will be approximately 573278 new cases of bladder cancer worldwide in 2020, or 3.2% of all cancers.

Request for a sample of the report browse through- https://univdatos.com/get-a-free-sample-form-php/?product_id=30863

Based on cancer type, the market is segmented into bladder cancer, urethral cancer, and ureteric and renal pelvic cancer. Among them, the bladder cancer category is to witness a significant CAGR during the forecast period. This is mainly due to rising cases of bladder cancer globally due to high tobacco consumption. For instance, according to the World Cancer Research Fund International, bladder cancer is the 10th most common cancer worldwide. It is the 6th most common cancer in men and the 17th most common cancer in women. There were more than 573,000 new cases of bladder cancer in 2020.

On the basis of treatment type, the market is categorized into chemotherapy and immunotherapy. Among these, immunotherapy to hold a significant share of the market in 2020. Immunotherapy boosts our body’s ability to fight cancer by encouraging the immune system to produce more immune cells that fight cancer. Moreover, recent clinical trials and drug approval will also contribute to the growth of the market during the forecast period. For instance, Updated data from the global Phase 2 study (CORE1) of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) were announced by CG Oncology.

For a detailed analysis of the Global Urinary Tract Cancer Market browse through – https://univdatos.com/report/urgent-care-apps-market/

For a better understanding of the market adoption of the urinary tract cancer industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the rising research and development initiatives, increasing incidents of bladder cancer coupled with the rising geriatric population. In addition, the increasing presence of major pharmaceutical companies in the region coupled with their increasing focus on the research and development of new drugs is further expected to propel the market growth.

Some of the major players operating in the market include F. Hoffmann-La Roche, AstraZeneca plc, Bristol-Myers Squibb, Merck & Co Inc., Johnson & Johnson, Eli Lilly and Co., GlaxoSmithKline plc, Novartis International AG, Pfizer Inc., Sanofi, and Astellas Pharma Inc.

Global Urinary Tract Cancer Market Segmentation

Market Insight, by Cancer Type

• Bladder Cancer
• Urethral Cancer
• Ureteric and Renal Pelvic Cancer

Market Insight, by Treatment Type

• Chemotherapy
• Immunotherapy

Market Insight, by Distribution Channel

• Retail Pharmacy
• Online Pharmacy

Market Insight, by Region

• North America
  • US
  • Canada
  • Rest of North America
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
• Rest of the World

Top Company Profiles

• F. Hoffmann-La Roche
• AstraZeneca plc
• Bristol-Myers Squibb
• Merck & Co Inc.
• Johnson & Johnson
• Eli Lilly and Co.
• GlaxoSmithKline plc
• Novartis International AG
• Pfizer Inc.
• Astellas Pharma Inc.